Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor

The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is a major complication of hemophilia A treatment. The sole clinical therapy to restore FVIII tolerance in patients with inhibitors remains immune tolerance induction (ITI) which is expensive, difficult to administer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Immunol
Hauptverfasser: Georgescu, Maria T., Moorehead, Paul C., Liu, Tongyao, Dumont, Jennifer, Scott, David W., Hough, Christine, Lillicrap, David
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2020
Schlagworte:
Immunology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7025534/
https://ncbi.nlm.nih.gov/pubmed/32117285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00138
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge